Skip to content

Study of the efficacy of hepatic arterial infusion therapy (modified Circadian chronotherapy) for unresectable colorectal cancer liver metastasis

Study of the efficacy of hepatic arterial infusion therapy (modified Circadian chronotherapy) for unresectable colorectal cancer liver metastasis - Study of the efficacy of hepatic arterial infusion therapy (modified Circadian chronotherapy) for unresectable colorectal cancer liver metastasis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000018215
Enrollment
28
Registered
2015-07-06
Start date
2015-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic liver cancer from colon and rectum

Interventions

Hepatic infusion therapy will be performed.

Sponsors

Yokohama City University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.It has been confirmed that it is histologically colon and rectum cancer 2.Diagnosis of stage 4 has been confirmed liver metastases in the diagnostic imaging 3.There is no distant metastasis other than liver, lung, and peritoneal dissemination 4.More than 20yr 5.for registration before tumor organ function within two weeks, it meets the following criteria. Incidentally, if the inspection result within that period there are a plurality and adopting those registered most recently, is not performed transfusion, administration of hematopoietic factors preparations building within two weeks before the test date When measurement white blood cell number 4000/mm3 or more 12000/mm3 less than neutrophil number 2000/mm3 or more platelet count 10.0x4/m3 or more hemoglobin 9.0g/dl or more total bilirubin 2.0mg /dl or less AST. ALT. 200U/L or less than 1.5 times the serum creatinine facility reference value upper limit 6.there is no clinically problem of the electrocardiogram within registration before 4 weeks 7.The Eastern Cooperative Oncology Group(ECOG) Performance Status =0-1 8.received a sufficient explanation for the study content, written consent of the person has been obtained

Exclusion criteria

Exclusion criteria: Patient other than the above

Design outcomes

Primary

MeasureTime frame
Efficacy

Secondary

MeasureTime frame
Safety

Countries

Japan

Contacts

Public ContactKazuhisa Takeda

Yokohama City University Hospital Gastroenterological surgery

kazutake@yokohama-cu.ac.jp045-787-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026